Syntis Bio, a Boston, MA-based clinical-stage biopharmaceutical firm growing oral therapies for weight problems, diabetes and uncommon illnesses, raised $38M in Collection A funding.
The spherical was led by Cerberus Ventures with participation from new buyers Mansueto Investments, Woori Enterprise Companions, Apollo Labs, BOLD Capital Companions, W. R. Berkley Company, Safar Companions, Portal Improvements, Colorcon Ventures and Cerity Companions Ventures.
The corporate intends to make use of the funds to increase operations and R&D efforts.
Led by CEO Rahul Dhanda, Syntis Bio is a clinical-stage biopharmaceutical firm growing oral therapies that harness the small gut’s distinctive biology to offer extra accessible, efficient and sustainable options throughout the healthcare spectrum, from uncommon genetic issues to the world’s most prevalent circumstances. It’s quickly advancing a pipeline of oral therapies engineered for focused exercise within the small gut, the physique’s nexus for metabolic management, digestion and drug absorption. Alongside its lead weight problems program, SYNT-101, the corporate is advancing a portfolio of therapies concentrating on orphan metabolic illnesses and intestinal-related issues.
Syntis has additionally secured as much as $5M in non-dilutive funding from the Nationwide Institutes of Well being (NIH) by means of two Quick-Monitor Small Enterprise Innovation Analysis (SBIR) awards from the Nationwide Institute of Diabetes and Digestive and Kidney Ailments (NIDDK), supporting the development of its SYNT™ (SYNthetic Tissue-lining) platform.
FinSMEs
01/07/2025
